Special Collections

Journal Club

The optimal timing to transition from a sphingosine-1-receptor (S1P) modulator to an anti-CD20 agent in certain patients with multiple sclerosis (MS) remains unclear. This Journal Club discussion focuses on an analysis of real-world data and the implications on clinical practice of the association between MS inflammatory activity and the transition period from an S1P modulator to an anti-CD20 agent in patients with MS.

Background Anti-CD20 therapies rapidly induce a significant depletion of peripheral B cells in patients with multiple sclerosis (MS). As individuals with MS have previously demonstrated impaired responses to COVID-19 vaccines, a study was undertaken to determine whether patients who receive a vaccine prior to initiation of anti-CD20 therapy will demonstrate better responses to a third…

Background Anti-CD20 therapy has been shown to be highly effective at depleting the existing population of immune B cells in patients with multiple sclerosis (MS).1 The goal of therapy is to remove impaired B cells from the immune system, setting the stage for repopulation with a healthier generation of new B cells. Little is known…